Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats.

Cisplatin (CDDP)-induced acute kidney injury (AKI) is a major clinical concern. CDDP treatment is generally conducted with multiple cycles; the magnitude of the CDDP-induced AKI may be altered by these cycles. Moreover, sub-chronic kidney injury (sCKI) induced by repeated CDDP treatment is often associated with renal interstitial fibrosis, potentially leading to chronic kidney disease. Therefore, it is suggested that the management of not only AKI but also sCKI induced by CDDP in multiple cycles plays an important role in the outcome of CDDP-based chemotherapy. This study investigated the alteration in pharmacokinetics and toxicodynamics of CDDP that was repeatedly administered for three cycles in rats; a cycle consisted of CDDP (5.0 mg/kg, bolus injection) followed by a 21-d washout period. AKI and sCKI were evaluated by plasma creatinine concentration. In repeated multiple administration of CDDP, renal clearance was decreased and the amounts of accumulated Pt in kidneys increased by the cycle. AKI and sCKI were similarly exacerbated by the cycle, whereas the degree of AKI showed a large inter- and intra-individual variation in each cycle. However, the degree of sCKI constantly increased (creatinine increasing ratio in any cycle is about 150%), suggesting that the degree of sCKI in any given cycle was predictable by monitoring the initial creatinine baseline. In this study, therefore, it is suggested that the evaluation of sCKI by monitoring creatinine concentration at base is important for the estimation of CDDP-induced nephrotoxicity. These results may provide useful information for more effective and safe CDDP-based chemotherapy with evidence-based dose adjustment.

[1]  Y. Mizushima,et al.  Studies on nephrotoxicity following a single and repeated administration of cis-diamminedichloroplatinum (CDDP) in rats. , 1987, The Tohoku journal of experimental medicine.

[2]  A. Yonezawa,et al.  Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. , 2010, Biochemical pharmacology.

[3]  H. Rakugi,et al.  Cardiovascular , Pulmonary , and Renal Pathology Autophagy Guards Against Cisplatin-Induced Acute Kidney Injury , 2012 .

[4]  Richard C. Taylor,et al.  Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy , 2016, American journal of clinical oncology.

[5]  Keizo Fukushima,et al.  Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity. , 2016, Journal of pharmaceutical sciences.

[6]  C. Edelstein,et al.  Cisplatin-Induced Acute Renal Failure Is Associated with an Increase in the Cytokines Interleukin (IL)-1β, IL-18, IL-6, and Neutrophil Infiltration in the Kidney , 2007, Journal of Pharmacology and Experimental Therapeutics.

[7]  T Nadasdy,et al.  Proliferative activity of intrinsic cell populations in the normal human kidney. , 1994, Journal of the American Society of Nephrology : JASN.

[8]  S. Mehta,et al.  Long-Term Renal Outcomes after Cisplatin Treatment. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[9]  O. Suzuki,et al.  Trace analysis of platinum in blood and urine by ESI-MS-MS , 2007, Forensic Toxicology.

[10]  J. Yamate,et al.  Participation of Different Macrophage Populations and Myofibroblastic Cells in Chronically Developed Renal Interstitial Fibrosis after Cisplatin-induced Renal Injury in Rats , 2002, Veterinary pathology.

[11]  O. Suzuki,et al.  Determination of platinum derived from cisplatin in human tissues using electrospray ionization mass spectrometry. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  F. Hernández,et al.  Lipid Peroxides and Antioxidant Enzymes in Cisplatin-Induced Chronic Nephrotoxicity in Rats , 2005, Mediators of inflammation.

[13]  J. Richie Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. , 2005, The Journal of urology.

[14]  M. Welch,et al.  Certification of creatinine in a human serum reference material by GC-MS and LC-MS. , 2007, Clinical chemistry.

[15]  K. Hanada,et al.  Pharmacokinetics and Toxicodynamics of Cisplatin and Its Metabolites in Rats: Relationship between Renal Handling and Nephrotoxicity of Cisplatin , 2000, The Journal of pharmacy and pharmacology.

[16]  H. Anders,et al.  Cell cycle control in the kidney. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  T. Boulikas,et al.  Low renal toxicity of lipoplatin compared to cisplatin in animals. , 2004, Anticancer research.

[18]  N. Sutandyo,et al.  Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[19]  K. Hanada,et al.  Pharmacokinetics and Toxicodynamics of Oxaliplatin in Rats: Application of a Toxicity Factor to Explain Differences in the Nephrotoxicity and Myelosuppression Induced by Oxaliplatin and the Other Platinum Antitumor Derivatives , 2010, Pharmaceutical Research.

[20]  J. Kim,et al.  Glutamine protects against cisplatin-induced nephrotoxicity by decreasing cisplatin accumulation. , 2015, Journal of pharmacological sciences.

[21]  A. Gibson,et al.  Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance , 2013, Clinical pharmacology and therapeutics.

[22]  A. Hishida,et al.  Role of the increase in p21 in cisplatin-induced acute renal failure in rats. , 2001, Journal of the American Society of Nephrology : JASN.

[23]  A. Sparreboom,et al.  Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin‐Induced Nephrotoxicity , 2009, Clinical pharmacology and therapeutics.

[24]  R. Safirstein,et al.  Cisplatin nephrotoxicity. , 2003, Seminars in nephrology.

[25]  G. Eknoyan,et al.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.

[26]  D. Guinee,et al.  Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy , 1993, Cancer.

[27]  W Wolf,et al.  Preparation and metabolism of a cisplatin/serum protein complex. , 1980, Chemico-biological interactions.

[28]  T. Nakao,et al.  Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. , 2006, Journal of pharmacological sciences.

[29]  M. Puglia,et al.  Cisplatin-induced kidney injury in the rat: L-carnitine modulates the relationship between MMP-9 and TIMP-3. , 2009, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[30]  A. Khwaja KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.